These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29315113)

  • 1. Integrase Resistance-Associated Mutations on Raltegravir Failure in Western India: A Preliminary Analysis.
    Pujari SN; Gaikwad S; Joshi K; Dabhade D; Sane S; Rao NP; Bele V
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):e42-e45. PubMed ID: 29315113
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase-resistant HIV in an antiretroviral-naive patient in Australia.
    Rafiei N; Woolley I; Korman TM; Chibo D; Gooey M; McMahon JH
    AIDS; 2017 Feb; 31(4):598-600. PubMed ID: 28118237
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Resistance to integrase inhibitors].
    Garrido C; de Mendoza C; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():40-6. PubMed ID: 19572425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
    Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
    Grobler JA; Hazuda DJ
    Curr Opin Virol; 2014 Oct; 8():98-103. PubMed ID: 25128610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of dolutegravir failure with R263K mutation.
    Cardoso M; Baptista T; Diogo I; Aleixo MJ; Marques N; Mansinho K; Gomes P
    AIDS; 2018 Nov; 32(17):2639-2640. PubMed ID: 30379690
    [No Abstract]   [Full Text] [Related]  

  • 12. Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
    Chehadeh W; Albaksami O; Al-Shammari S
    Antivir Chem Chemother; 2020; 28():2040206620927908. PubMed ID: 32434393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 14. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
    Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
    AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences.
    Mikasi SG; Isaacs D; Ikomey GM; Shimba H; Cloete R; Jacobs GB
    AIDS Res Hum Retroviruses; 2021 Jan; 37(1):54-56. PubMed ID: 32640829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
    Ambrosioni J; Rico JÁF; Nicolás D; Mosquera MM; de Lazzari E; Marcos MÁ; García F; Miró JM;
    AIDS; 2019 Aug; 33(10):1613-1617. PubMed ID: 31090546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    Yotsumoto M; Hachiya A; Ichiki A; Amano K; Kinai E
    AIDS; 2020 Nov; 34(14):2155-2157. PubMed ID: 32932342
    [No Abstract]   [Full Text] [Related]  

  • 19. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 20. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
    Reuman EC; Bachmann MH; Varghese V; Fessel WJ; Shafer RW
    Antimicrob Agents Chemother; 2010 Feb; 54(2):934-6. PubMed ID: 19917747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.